<DOC>
	<DOCNO>NCT00316693</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Indeed , certain oncogenic type HPV infect cervix ( part uterus womb ) . This infection may go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . This study evaluate efficacy prevention persistent HPV-16 HPV-18 cervical infection last least 6 month , immunogenicity safety GSK Biologicals HPV-16/18 vaccine ( Cervarix TM ) 24 month Japanese adult woman age 20 - 25 year age study start . Approximately 1000 study subject either receive HPV vaccine control vaccine ( Hepatitis A vaccine ) administer intramuscularly accord 0-1-6 month schedule . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Human Papillomavirus ( HPV ) Vaccine ( Cervarix TM ) Efficacy , Immunogenicity &amp; Safety Trial Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine</brief_title>
	<detailed_description>The Protocol Posting update reflect change consequence amendment protocol . Sections impact Official Title study Intervention name .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator/coinvestigator believe comply requirement protocol enrol study . A Japanese female subject , include , 20 25 year age time first vaccination . Written inform consent obtain subject prior enrolment . Healthy subject establish medical history historyoriented clinical examination enter study . Subjects must negative urine pregnancy test . Subjects must nonchildbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Subject must intact cervix Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine/control within 30 day precede first dose study vaccine/control , plan use study period . Pregnant breastfeed woman . Women must least 3 month postpregnancy breastfeed enter study . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution study period , 2 month last vaccine dose previous administration component investigational vaccine Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Routine vaccine may allow 8 day first dose study vaccine . Previous vaccination HPV . History vaccination hepatitis A known clinical history hepatitis A disease Administration immunoglobulin and/or blood product within three month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History allergic disease reaction likely exacerbate component study vaccine Hypersensitivity latex Known acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History colposcopy plan colposcopy evaluate abnormal cervical cytology ( Pap smear ) test . Heavy bleed heavy vaginal discharge pelvic examination perform Acute disease time enrolment . Oral temperature &gt; = 37.5°C / axillary temperature &gt; 37.5°C . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV Vaccine Efficacy</keyword>
</DOC>